1260629-37-5

Basic information

• Product Name: C₂₈H₃₈ClN₅O₂
• CAS NO: 1260629-37-5
• Molecular Weight: 512.095
• Mol File: 1260629-37-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₈H₃₈ClN₅O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₈H₃₈ClN₅O₂(1260629-37-5)
• EPA Substance Registry System: C₂₈H₃₈ClN₅O₂(1260629-37-5)

Safety Data

• Hazardous Substances Data: 1260629-37-5(Hazardous Substances Data)

Upstream product

• 150812-36-5 tert-butyl 4-(pyridin-3-ylmethyl)piperazine-1-carboxylate 
• 333985-70-9 1-acetyl-piperidine-4-carboxylic acid (3-chloro-4-methyl-phenyl)-(3-chloro-propyl)-amide 
• 39244-80-9 1-(pyridin-3-ylmethyl)piperazine 

Relevant articles and documents

Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors

A series of novel 1,4-disubstituted piperidine/piperazine derivatives were designed, synthesized and evaluated for their in vitro activities against HIV-1 Bal (R5) infection in CEMX174 5.25M7 cells. A majority of these compounds showed potent anti-HIV-1 activities with IC50 at nanomolar levels. N-(4-Fluoro-benzyl)piperazine analog B07 hydrochloride exhibited potency against HIV-1 activity similar to that of TAK-220 hydrochloride, but it had much better water solubility (25 mg/ml in phosphate sodium buffer at 25 °C) and oral bioavailability (56%) than TAK-220 hydrochloride (a solubility of 2 mg/ml and oral bioavailability of 1.4%). These results suggest that B07 hydrochloride may serve as a better lead for the development of new anti-HIV-1 therapies or microbicides for treatment and prevent of HIV-1 infection.